Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic Hepatitis B

[Guest guest]

Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic

Hepatitis B Patients

Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26

that its Baraclude - generic name: entecavir - had been certifiied by

Japan's Health, Labor and Welfare Ministry.

Baraclude is an anti-viral action drug for treatment of chronic hepatitis B

virus infection in adults with evidence of active viral replication and

either evidence of persistent elevations in serum aminotransferases or

histologically active disease.

The drug has proven an effective inhibitor of virus replication and has

indicated improvements in the increase of alanine aminotransferase (ALT) and

overall liver health.

Baraclude has shown much more benefit over Lamivudine, based on the clinical

trials in 5 continents worldwide. the medication has already been approved

in 2005 by the Food and Drug Administration in the US, as well as in

countries worldwide.

By Aki Tsukioka, JCN Staff Writer

http://japancorp.net/Article.Asp?Art_ID=12964

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic

Hepatitis B Patients

Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26

that its Baraclude - generic name: entecavir - had been certifiied by

Japan's Health, Labor and Welfare Ministry.

Baraclude is an anti-viral action drug for treatment of chronic hepatitis B

virus infection in adults with evidence of active viral replication and

either evidence of persistent elevations in serum aminotransferases or

histologically active disease.

The drug has proven an effective inhibitor of virus replication and has

indicated improvements in the increase of alanine aminotransferase (ALT) and

overall liver health.

Baraclude has shown much more benefit over Lamivudine, based on the clinical

trials in 5 continents worldwide. the medication has already been approved

in 2005 by the Food and Drug Administration in the US, as well as in

countries worldwide.

By Aki Tsukioka, JCN Staff Writer

http://japancorp.net/Article.Asp?Art_ID=12964

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic

Hepatitis B Patients

Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26

that its Baraclude - generic name: entecavir - had been certifiied by

Japan's Health, Labor and Welfare Ministry.

Baraclude is an anti-viral action drug for treatment of chronic hepatitis B

virus infection in adults with evidence of active viral replication and

either evidence of persistent elevations in serum aminotransferases or

histologically active disease.

The drug has proven an effective inhibitor of virus replication and has

indicated improvements in the increase of alanine aminotransferase (ALT) and

overall liver health.

Baraclude has shown much more benefit over Lamivudine, based on the clinical

trials in 5 continents worldwide. the medication has already been approved

in 2005 by the Food and Drug Administration in the US, as well as in

countries worldwide.

By Aki Tsukioka, JCN Staff Writer

http://japancorp.net/Article.Asp?Art_ID=12964

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic

Hepatitis B Patients

Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26

that its Baraclude - generic name: entecavir - had been certifiied by

Japan's Health, Labor and Welfare Ministry.

Baraclude is an anti-viral action drug for treatment of chronic hepatitis B

virus infection in adults with evidence of active viral replication and

either evidence of persistent elevations in serum aminotransferases or

histologically active disease.

The drug has proven an effective inhibitor of virus replication and has

indicated improvements in the increase of alanine aminotransferase (ALT) and

overall liver health.

Baraclude has shown much more benefit over Lamivudine, based on the clinical

trials in 5 continents worldwide. the medication has already been approved

in 2005 by the Food and Drug Administration in the US, as well as in

countries worldwide.

By Aki Tsukioka, JCN Staff Writer

http://japancorp.net/Article.Asp?Art_ID=12964

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/